


WHAT IS CLAIMED IS:

1. A compound of formula I, or a salt or
prodrug thereof:



(I)


wherein the broken circle represents two non-adjacent double bonds in any position in the five-membered ring; two, three or four of V, W, X, Y and Z represent nitrogen and the remainder represent carbon provided that, when two of V, W, X, Y and Z represent nitrogen and the remainder represent carbon, then the said nitrogen atoms are in non-adjacent positions within the five-membered ring;

A¹ is selected from the group consisting of, hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, -OR^x, -SR^x, -NR^xR^y, -NR^xCOR^y, -NR^xCO₂R^y, -NR^xSO₂R^y, and -NR^xCTNR^xR^y;

A² represents a non-bonded electron pair when four of V, W, X, Y and Z represent nitrogen and the other represents carbon; or, when two or three of V, W, X, Y and Z represent nitrogen and the remainder represent carbon, A² is selected from the group consisting of hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, -OR^x, -SR^x, -NR^xR^y, -NR^xCOR^y, -NR^xCO₂R^y, -NR^xSO₂R^y, and -NR^xCTNR^xR^y;

E represents a bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms;

F represents a group of formula




U represents nitrogen or C-R²;

B represents oxygen, sulphur or N-R³;

R¹ represents -CH₂.CHR⁴.NR⁶R⁷ or a group of

15 formula



25 in which the broken line represents an optional chemical bond;

R², R³, R⁴, R⁵, R⁶ and R⁷ independently represent hydrogen or C₁₋₆ alkyl;


R^x and R^y independently represent hydrogen, hydrocarbon or a heterocyclic group, or R^x and R^y together represent a C₂₋₆ alkylene group;

30 R^z represents hydrogen, hydrocarbon or a heterocyclic group;

T represents oxygen, sulphur or a group of formula =N.G; and

G represents hydrocarbon, a heterocyclic group or an electron-withdrawing group.

2. A compound according to claim 1
5 represented by formula IIA, and salts and prodrugs thereof:



15 wherein

X¹ represents nitrogen or A¹²-C;

n is zero, 1, 2 or 3;


B¹ represents oxygen, sulphur or N-R¹³;

A¹¹ and A¹² are independently selected from the
20 group consisting of C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, aryl, aryl(C₁₋₆)alkyl, C₃₋₇ heterocycloalkyl, heteroaryl and heteroaryl(C₁₋₆)alkyl, any of which groups may be optionally substituted; and hydrogen, halogen, cyano, trifluoromethyl, C₁₋₆ alkoxy,
25 C₁₋₆ alkylthio and -NR^xR^y;

R¹², R¹³, R¹⁴, R¹⁶ and R¹⁷ independently represent hydrogen or C₁₋₆ alkyl; and

R^x and R^y independently represent hydrogen, hydrocarbon or a heterocyclic group, or R^x and R^y together
30 represent a C₂₋₆ alkylene group.

3. A compound according to claim 1 represented by formula IIB, and salts and prodrugs thereof:



(IIB)

10 wherein

Y¹ represents nitrogen or A²²-C;

n is zero, 1, 2 or 3;

B² represents oxygen, sulphur or N-R²³;

15 A²¹ and A²² are independently selected from the group consisting of C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, aryl, aryl(C₁₋₆)alkyl, C₃₋₇

heterocycloalkyl, heteroaryl and heteroaryl(C₁₋₆)alkyl,

any of which groups may be optionally substituted; and


hydrogen, halogen, cyano, trifluoromethyl, C₁₋₆ alkoxy, C₁₋₆ alkylthio and -NR^xR^y;

20 R²², R²³, R²⁴, R²⁶ and R²⁷ independently represent hydrogen or C₁₋₆ alkyl; and

R^x and R^y independently represent hydrogen, hydrocarbon or a heterocyclic group, or R^x and R^y together represent a C₂₋₆ alkylene group.

25 4. A compound according to claim 1 represented by formula IIC, and salts and prodrugs thereof:

30



wherein

Y^2 represents nitrogen or $A^{32}-C$;

Z^1 represents nitrogen or CH;

n is zero, 1, 2 or 3;

15 B^3 represents oxygen, sulphur or $N-R^{33}$;

A^{31} and A^{32} are independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, aryl, aryl(C_{1-6})alkyl, C_{3-7}

20 heterocycloalkyl, heteroaryl and heteroaryl(C_{1-6})alkyl, any of which groups may be optionally substituted; and hydrogen, halogen, cyano, trifluoromethyl, C_{1-6} alkoxy, C_{1-6} alkylthio and $-NR^X R^Y$;

R^{31} represents $-CH_2.CHR^{34}.NR^{36}R^{37}$ or a group of formula


25



R^{32} , R^{33} , R^{34} , R^{35} , R^{36} and R^{37} independently represent hydrogen or C_{1-6} alkyl; and

R^x and R^y independently represent hydrogen, hydrocarbon or a heterocyclic group, or R^x and R^y together represent a C_{2-6} alkylene group.

5. A compound according to claim 1 represented by formula IID, and salts and prodrugs thereof:



(IID)

wherein

W^1 represents nitrogen or $C-A^{42}$;

n is zero, 1, 2 or 3;

B^4 represents oxygen, sulphur or $N-R^{43}$;

A^{41} and A^{42} are independently selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, aryl, aryl(C_{1-6})alkyl, C_{3-7} heterocycloalkyl, heteroaryl and heteroaryl(C_{1-6})alkyl, any of which groups may be optionally substituted; and hydrogen, halogen, cyano, trifluoromethyl, C_{1-6} alkoxy, C_{1-6} alkylthio and $-NR^xR^y$;

R^{41} represents $-CH_2.CHR^{44}.NR^{46}R^{47}$ or a group of formula



10 R^{42} , R^{43} , R^{44} , R^{45} , R^{46} and R^{47} independently
represent hydrogen or C_{1-6} alkyl; and
 R^x and R^y independently represent hydrogen,
hydrocarbon or a heterocyclic group, or R^x and R^y together
represent a C_{2-6} alkylene group.

15 6. A compound according to claim 1 selected
from:
2-[5-(2-benzyltetrazol-5-ylmethyl)-1H-indol-3-
yl]ethylamine;
2-[5-(1-benzyltetrazol-5-ylmethyl)-1H-indol-3-
20 yl]ethylamine;
N,N-dimethyl-2-[5-(1-methyltetrazol-5-ylmethyl)-1H-indol-
3-yl]ethylamine;
N,N-dimethyl-2-[5-(2-methyltetrazol-5-ylmethyl)-1H-indol-
3-yl]ethylamine;
25 N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-
yl]ethylamine;
N,N-dimethyl-2-[5-(tetrazol-2-ylmethyl)-1H-indol-3-
yl]ethylamine;
N,N-dimethyl-2-[5-(tetrazol-1-ylmethyl)-1H-indol-3-
30 yl]ethylamine;
N,N-dimethyl-2-[5-(1-methyl-1,2,4-triazol-5-ylmethyl)-1H-
indol-3-yl]ethylamine;
N,N-dimethyl-2-[5-(1-methyl-1,2,4-triazol-3-ylmethyl)-1H-
indol-3-yl]ethylamine;

N,N-dimethyl-2-[5-(1,2,3-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine;

5 3-(2-aminoethyl)-5-(1-methyltetrazol-5-yl)-benzo[b]thiophene;

3-(2-aminoethyl)-5-(2-methyltetrazol-5-yl)-benzo[b]thiophene;

3-[2-(N,N-dimethylamino)ethyl]-5-(2-methyltetrazol-5-yl)benzo[b]thiophene;

10 N,N-dimethyl-2-[5-(2-methylimidazol-1-ylmethyl)-1H-indol-3-yl]ethylamine;

N,N-dimethyl-2-[5-(imidazol-1-ylmethyl)-1H-indol-3-yl]ethylamine;

N,N-dimethyl-2-[5-(2-methylimidazol-1-yl)-1H-indol-3-yl]ethylamine;

15 N,N-dimethyl-2-[5-(2-ethyltetrazol-5-ylmethyl)-1H-indol-3-yl]ethylamine;

N,N-dimethyl-2-[5-(1-ethyltetrazol-5-ylmethyl)-1H-indol-3-yl]ethylamine;

N,N-dimethyl-2-[5-(1,2,4-triazol-1-yl)-1H-indol-3-yl]ethylamine;

20 1-methyl-4-[5-(2-methylimidazol-1-yl)-1H-indol-3-yl]piperidine;

1-methyl-4-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]piperidine;

25 4-[5-(2-methylimidazol-1-yl)-1H-indol-3-yl]piperidine;

4-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]piperidine;

3-[5-(2-methylimidazol-1-yl)-1H-indol-3-yl]pyrrolidine;

1-methyl-3-[5-(2-methylimidazol-1-yl)-1H-indol-3-yl]pyrrolidine;

30 4-[5-(imidazol-1-yl)-1H-indol-3-yl]piperidine;

4-[5-(1,2,3-triazol-1-yl)-1H-indol-3-yl]piperidine;

1-methyl-4-[5-(imidazol-1-yl)-1H-indol-3-yl]piperidine;

1-methyl-4-[5-(1,2,3-triazol-1-yl)-1H-indol-3-yl]piperidine;

- 1-methyl-3-[5-(1,2,3-triazol-1-yl)-1H-indol-3-yl]pyrrolidine;
1-methyl-3-[5-(2-methylimidazol-1-ylmethyl)-1H-indol-3-yl]pyrrolidine;
5 1-methyl-3-[5-(imidazol-1-yl)-1H-indol-3-yl]pyrrolidine;
1-methyl-3-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]pyrrolidine;
1-methyl-3-[5-(imidazol-1-ylmethyl)-1H-indol-3-yl]pyrrolidine;
10 N,N-dimethyl-2-[5-(2-aminoimidazol-1-yl)-1H-indol-3-yl]ethylamine;
N,N-dimethyl-2-[5-(2-aminoimidazol-1-ylmethyl)-1H-indol-3-yl]ethylamine;
N-methyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethylamine;
15 and salts and prodrugs thereof.

7. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in
20 association with a pharmaceutically acceptable carrier or excipient.

8. A method for the treatment and/or prevention of clinical conditions for which a selective agonist of 5-HT₁-like receptors is indicated, which
25 method comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.

Sub
a2

Add
a3

- add
C1